- Home
- PPT vs IMMP Comparison
PPT vs IMMP Comparison
Compare PPT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPT
- IMMP
- Stock Information
- Founded
- PPT 1988
- IMMP 1987
- Country
- PPT United States
- IMMP Australia
- Employees
- PPT N/A
- IMMP N/A
- Industry
- PPT Finance Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PPT Finance
- IMMP Health Care
- Exchange
- PPT Nasdaq
- IMMP Nasdaq
- Market Cap
- PPT 338.4M
- IMMP 304.0M
- IPO Year
- PPT N/A
- IMMP N/A
- Fundamental
- Price
- PPT $3.56
- IMMP $1.98
- Analyst Decision
- PPT
- IMMP Buy
- Analyst Count
- PPT 0
- IMMP 2
- Target Price
- PPT N/A
- IMMP $8.50
- AVG Volume (30 Days)
- PPT 156.1K
- IMMP 95.6K
- Earning Date
- PPT 01-01-0001
- IMMP 02-27-2025
- Dividend Yield
- PPT 8.84%
- IMMP N/A
- EPS Growth
- PPT N/A
- IMMP N/A
- EPS
- PPT N/A
- IMMP N/A
- Revenue
- PPT N/A
- IMMP $2,563,302.00
- Revenue This Year
- PPT N/A
- IMMP N/A
- Revenue Next Year
- PPT N/A
- IMMP $47.79
- P/E Ratio
- PPT N/A
- IMMP N/A
- Revenue Growth
- PPT N/A
- IMMP 9.59
- 52 Week Low
- PPT $3.25
- IMMP $1.66
- 52 Week High
- PPT $3.72
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PPT 50.31
- IMMP 46.29
- Support Level
- PPT $3.53
- IMMP $1.90
- Resistance Level
- PPT $3.58
- IMMP $2.05
- Average True Range (ATR)
- PPT 0.03
- IMMP 0.09
- MACD
- PPT 0.00
- IMMP -0.02
- Stochastic Oscillator
- PPT 55.00
- IMMP 19.44
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.